Ratings Omda

Equities

CSAM

NO0010894512

Market Closed - Oslo Bors Other stock markets 15:45:00 03/05/2024 BST			5-day change	1st Jan Change
35.9 ^NOK	-0.28%		+3.16%	-2.97%

04-25	Omda AS Announces Board Appointments	CI
03-01	Tranche Update on Omda AS (OB:OMDA)'s Equity Buyback Plan announced on January 30, 2023.	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 79.98 and 32.05 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OMDA	-2.97%	66.55M		-
PRO MEDICUS LIMITED	+18.46%	7.66B		C-
SECTRA AB	+22.71%	3.85B		B-
EVOLENT HEALTH, INC.	-17.95%	3.14B		C-
OMNICELL, INC.	-19.93%	1.35B		B
LUNIT INC.	-30.65%	1.18B		-
SIMULATIONS PLUS, INC.	+4.36%	934M		C
B-SOFT CO.,LTD.	-34.81%	911M		-
VERADIGM INC.	-26.60%	840M	-	C+
SURGICAL SCIENCE SWEDEN AB	-15.56%	726M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes